-
公开(公告)号：US07067554B2
公开(公告)日：2006-06-27
申请号：US10611741
申请日：2003-07-01
申请人： Adnan M. M. Mjalli , Ramesh Gopalaswamy , Kwasi A. Avor , Christopher L. Wysong , Patron Andrew
发明人： Adnan M. M. Mjalli , Ramesh Gopalaswamy , Kwasi A. Avor , Christopher L. Wysong , Patron Andrew
IPC分类号： A61K31/21 , C07C233/00
CPC分类号： C07C311/19 , A61K31/16 , C07C237/20 , C07C237/22 , C07C271/22 , C07C275/24 , C07C279/14 , C07C311/06 , C07D307/42 , Y10S977/915
摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
-
2.发明授权公开(公告)号：US07737285B2
公开(公告)日：2010-06-15
申请号：US11800085
申请日：2007-05-03
申请人： Adnan M. M. Mjalli , Robert C. Andrews , Ramesh Gopalaswamy , Anitha Hari , Kwasi A. Avor , Ghassan Qabaja , Xiao-Chuan Guo , Suparna Gupta , David R. Jones , Xin Chen
发明人： Adnan M. M. Mjalli , Robert C. Andrews , Ramesh Gopalaswamy , Anitha Hari , Kwasi A. Avor , Ghassan Qabaja , Xiao-Chuan Guo , Suparna Gupta , David R. Jones , Xin Chen
IPC分类号： C07D233/61 , A01N43/50
CPC分类号： C07D233/64 , C07D235/08 , C07D235/12 , C07D235/14 , C07D235/18 , C07D235/30 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D413/12 , C07D453/02
摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
摘要翻译： 本发明提供某些化合物，其制备方法，包含该化合物的药物组合物及其在治疗人或动物疾病中的用途。 本发明的化合物可用作晚期糖基化终产物（RAGE）的受体与其配体如晚期糖基化终产物（AGE），S100 /钙粒蛋白/ EN-RAGE，淀粉样蛋白和 两性霉素，以及由RAGE引起的人类疾病的管理，治疗，控制或辅助治疗。 这些疾病或疾病状态包括急性和慢性炎症，糖尿病晚期并发症的发展，例如血管通透性增加，肾病，动脉粥样硬化和视网膜病变，阿尔茨海默病的发展，勃起功能障碍和肿瘤侵袭和转移。
-
公开(公告)号：US07714013B2
公开(公告)日：2010-05-11
申请号：US11511163
申请日：2006-08-28
申请人： Adnan M. M. Mjalli , Robert C. Andrews , Ramesh Gopalaswamy , Anitha Hari , Kwasi A. Avor , Ghassan Qabaja , Xiao-Chuan Guo , Suparna Gupta , David R. Jones , Xin Chen
发明人： Adnan M. M. Mjalli , Robert C. Andrews , Ramesh Gopalaswamy , Anitha Hari , Kwasi A. Avor , Ghassan Qabaja , Xiao-Chuan Guo , Suparna Gupta , David R. Jones , Xin Chen
IPC分类号： A61K31/4164 , A61K31/4178 , C07D233/64 , C07D403/02
CPC分类号： C07D233/64 , C07D235/08 , C07D235/12 , C07D235/14 , C07D235/18 , C07D235/30 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D413/12 , C07D453/02
摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
-
公开(公告)号：US06613801B2
公开(公告)日：2003-09-02
申请号：US09799317
申请日：2001-03-05
申请人： Adnan M. M. Mjalli , Ramesh Gopalaswamy , Kwasi S. Avor , Christopher L. Wysong , Andrew Patron
发明人： Adnan M. M. Mjalli , Ramesh Gopalaswamy , Kwasi S. Avor , Christopher L. Wysong , Andrew Patron
IPC分类号： A61K3127
CPC分类号： C07C311/19 , A61K31/16 , C07C237/20 , C07C237/22 , C07C271/22 , C07C275/24 , C07C279/14 , C07C311/06 , C07D307/42 , Y10S977/915
摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, &bgr;-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
-
公开(公告)号：US07776919B2
公开(公告)日：2010-08-17
申请号：US12019045
申请日：2008-01-24
IPC分类号： A01N37/18 , C07C237/00 , C07C233/00 , C07C235/00
CPC分类号： C07D231/12 , C07C235/38 , C07C237/20 , C07C271/22 , C07C2601/08 , C07C2603/18 , C07D207/16 , C07D211/34 , C07D217/26 , C07D233/56 , C07D249/08 , C07D309/04
摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
摘要翻译： 本发明提供某些化合物，其制备方法，包含该化合物的药物组合物及其在治疗人或动物疾病中的用途。 本发明的化合物可用作晚期糖基化终产物（RAGE）的受体与其配体如晚期糖基化终产物（AGE），S100 /钙粒蛋白/ EN-RAGE，淀粉样蛋白和 两性霉素，以及由RAGE引起的人类疾病的管理，治疗，控制或辅助治疗。 这些疾病或疾病状态包括急性和慢性炎症，糖尿病晚期并发症的发展，例如血管通透性增加，肾病，动脉粥样硬化和视网膜病变，阿尔茨海默病的发展，勃起功能障碍和肿瘤侵袭和转移。
-
公开(公告)号：US07763726B2
公开(公告)日：2010-07-27
申请号：US11704431
申请日：2007-02-09
申请人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
发明人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
IPC分类号： A61K31/496 , C07D401/14 , C07D403/14
摘要： The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
-
7.发明授权Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors 失效苯并唑衍生物，组合物和用作极光激酶抑制剂的方法公开(公告)号：US08377983B2
公开(公告)日：2013-02-19
申请号：US12703604
申请日：2010-02-10
申请人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
发明人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
IPC分类号： A01N43/38 , A01N43/52 , A61K31/405 , A61K31/497 , A61K31/535 , A61K31/415 , C07D403/00 , C07D405/00 , C07D409/00 , C07D411/00
CPC分类号： C07D417/14 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D487/04
摘要： The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
摘要翻译： 本发明涉及治疗癌症的化合物和方法。 本发明提供抑制极光激酶的化合物，包含抑制极光激酶的化合物的药物组合物，以及使用本发明化合物或包含本发明化合物的药物组合物治疗癌症的方法。
-
8.发明授权公开(公告)号：US07361678B2
公开(公告)日：2008-04-22
申请号：US10382203
申请日：2003-03-05
申请人： Adnan M. M. Mjalli , Robert C. Andrews , Ramesh Gopalaswamy , Anitha Hari , Kwasi S. Avor , Ghassan Qabaja , Xiao-Chuan Guo , Suparna Gupta , David R. Jones , Xin Chen
发明人： Adnan M. M. Mjalli , Robert C. Andrews , Ramesh Gopalaswamy , Anitha Hari , Kwasi S. Avor , Ghassan Qabaja , Xiao-Chuan Guo , Suparna Gupta , David R. Jones , Xin Chen
IPC分类号： A61K31/4164 , A61K31/4178 , C07D233/64 , C07D403/02
CPC分类号： C07D233/64 , C07D235/08 , C07D235/12 , C07D235/14 , C07D235/18 , C07D235/30 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D413/12 , C07D453/02
摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
摘要翻译： 本发明提供某些化合物，其制备方法，包含该化合物的药物组合物及其在治疗人或动物疾病中的用途。 本发明的化合物可用作晚期糖基化终产物（RAGE）的受体与其配体如晚期糖基化终产物（AGE），S100 /钙粒蛋白/ EN-RAGE，β-淀粉样蛋白和两性蛋白之间相互作用的调节剂 ，以及由RAGE引起的人类疾病的管理，治疗，控制或辅助治疗。 这些疾病或疾病状态包括急性和慢性炎症，糖尿病晚期并发症的发展，例如血管通透性增加，肾病，动脉粥样硬化和视网膜病变，阿尔茨海默病的发展，勃起功能障碍和肿瘤侵袭和转移。
-
公开(公告)号：US07087632B2
公开(公告)日：2006-08-08
申请号：US10091609
申请日：2002-03-05
IPC分类号： A61K31/4184 , C07D235/14
CPC分类号： A61K31/4188 , C07D235/14 , C07D235/16
摘要： This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
-
10.发明授权Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors 有权苯并唑衍生物，组合物和用作极光激酶抑制剂的方法公开(公告)号：US07820821B2
公开(公告)日：2010-10-26
申请号：US11704431
申请日：2007-02-09
申请人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
发明人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
IPC分类号： A61K31/496 , C07D401/14 , C07D403/14
CPC分类号： C07D417/14 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D487/04
摘要： The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
摘要翻译： 本发明涉及治疗癌症的化合物和方法。 本发明提供抑制极光激酶的化合物，包含抑制极光激酶的化合物的药物组合物，以及使用本发明化合物或包含本发明化合物的药物组合物治疗癌症的方法。
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.063 秒)
